Biogen advances anti-tau Alzheimer’s drug diranersen despite mixed Phase 2 results on May 15, 2026 Alzheimer 's disease Biogen CELIA diranersen Ionis Pharmaceuticals Mental deterioration Phase 2 trial registrational development uridine triacetate +
Biogen advances Alzheimer’s tau program despite midphase miss on May 14, 2026 Benefit Biogen Biological Markers Cognitive diranersen Phase 2 Phase 3 registrational development uridine triacetate +